ZeCardio Therapeutics
-
DATABASE (8)
-
ARTICLES (3)
Founder of TreeFrog Therapeutics
Maxime Feyeux is President, CSO and co-founder of TreeFrog Therapeutics whose proprietory C-Stem technology mass-produces high-quality pluripotent stem cells in a 3D environment. Prior to founding TreeFrog in 2018, Feyeux worked as a maturation engineer at Aquitaine Science Transfert and completed a post-doctoral degree at Bordeaux’s Institut des Maladies Neurodégénératives. He also has a post-doctoral degree from the University of Geneva and completed his PhD in neurobiology and neurosciences at the Université d’Evry-Val d’Essone.
Maxime Feyeux is President, CSO and co-founder of TreeFrog Therapeutics whose proprietory C-Stem technology mass-produces high-quality pluripotent stem cells in a 3D environment. Prior to founding TreeFrog in 2018, Feyeux worked as a maturation engineer at Aquitaine Science Transfert and completed a post-doctoral degree at Bordeaux’s Institut des Maladies Neurodégénératives. He also has a post-doctoral degree from the University of Geneva and completed his PhD in neurobiology and neurosciences at the Université d’Evry-Val d’Essone.
Founder of TreeFrog Therapeutics
Kévin Alessandri is CEO, CTO and co-founder of TreeFrog Therapeutics, whose proprietory C-Stem technology mass-produces high-quality pluripotent stem cells in a 3D environment. Prior to founding TreeFrog in 2018, Alessandri spent two years as a post-doctoral fellow at Bordeaux’s Institut d’Optique. During 2014 and 2015, he completed a post-doctorate at the University of Geneva, focused on developing 3D printed microfluidics systems to build 3D cell culture vessels for stem cell applications. From 2008 to 2013 he completed a PhD on cellular capsules technology and applications at the Institut Curie in Paris.
Kévin Alessandri is CEO, CTO and co-founder of TreeFrog Therapeutics, whose proprietory C-Stem technology mass-produces high-quality pluripotent stem cells in a 3D environment. Prior to founding TreeFrog in 2018, Alessandri spent two years as a post-doctoral fellow at Bordeaux’s Institut d’Optique. During 2014 and 2015, he completed a post-doctorate at the University of Geneva, focused on developing 3D printed microfluidics systems to build 3D cell culture vessels for stem cell applications. From 2008 to 2013 he completed a PhD on cellular capsules technology and applications at the Institut Curie in Paris.
Founder of TreeFrog Therapeutics
Jean-Luc Treillou is co-founder of TreeFrog Therapeutics, whose proprietory C-Stem technology mass-produces high-quality pluripotent stem cells in a 3D environment. Since January 2019, he has also acted as an advisor and member of the strategic committee of IT security company Eshard. Prior to co-founding TreeFrog, Treillou founded YSOPIA Bioscience in 2011, where he was CEO until he left in 2021, and Chairman of the Board from 2018. Between 2009 and 2013 he held the posts of General Manager and Chairman of the Board at French R&D company Nutrionix.
Jean-Luc Treillou is co-founder of TreeFrog Therapeutics, whose proprietory C-Stem technology mass-produces high-quality pluripotent stem cells in a 3D environment. Since January 2019, he has also acted as an advisor and member of the strategic committee of IT security company Eshard. Prior to co-founding TreeFrog, Treillou founded YSOPIA Bioscience in 2011, where he was CEO until he left in 2021, and Chairman of the Board from 2018. Between 2009 and 2013 he held the posts of General Manager and Chairman of the Board at French R&D company Nutrionix.
DCVC (formerly Data Collective)
San Francisco-based DCVC, formerly named Data Collective, has made more than 400 investments in its 20 year history, with deep tech and science in general its key investment interests. It currently has 148 companies in its portfilio and has managed 48 exits to date, including acquisitions by Twitter and Amazon. Its most recent investments have included in the April 2021 £60m Series A round of British antibody medtech Alchemab Therapeutics and in the March 2021 $75m Series B round of Israeli blockchain development tool StarkWare Industries.
San Francisco-based DCVC, formerly named Data Collective, has made more than 400 investments in its 20 year history, with deep tech and science in general its key investment interests. It currently has 148 companies in its portfilio and has managed 48 exits to date, including acquisitions by Twitter and Amazon. Its most recent investments have included in the April 2021 £60m Series A round of British antibody medtech Alchemab Therapeutics and in the March 2021 $75m Series B round of Israeli blockchain development tool StarkWare Industries.
TreeFrog Therapeutics’ C-Stem technology mass-produces high-quality pluripotent stem cells in a 3D environment that mimics the way cells grow in the human body.
TreeFrog Therapeutics’ C-Stem technology mass-produces high-quality pluripotent stem cells in a 3D environment that mimics the way cells grow in the human body.
Asabys Partners is a VC firm based in Barcelona and invests mainly in the healthtech and biopharma industries. Backed by Sabadell Bank, the VC now has offices in Spain, UK, Switzerland and Israel. Asabys Partners aims to accelerate technology breakthroughs in the fields of science and medicine by supporting a network of industry experts and talent.Asabys started operations in 2019 and is currently fundraising its first fund, Sabadell Asabys Health Innovation Investments, with a target size of €70m and Banc Sabadell as anchor investor. Main areas of investment include Biopharma, MedTech and Digital Therapeutics.
Asabys Partners is a VC firm based in Barcelona and invests mainly in the healthtech and biopharma industries. Backed by Sabadell Bank, the VC now has offices in Spain, UK, Switzerland and Israel. Asabys Partners aims to accelerate technology breakthroughs in the fields of science and medicine by supporting a network of industry experts and talent.Asabys started operations in 2019 and is currently fundraising its first fund, Sabadell Asabys Health Innovation Investments, with a target size of €70m and Banc Sabadell as anchor investor. Main areas of investment include Biopharma, MedTech and Digital Therapeutics.
Rick Klausner is an award-winning scientist, former executive director of the Bill & Melinda Gates Foundation and an entrepreneur. Cell and molecular biologist Klausner was also director of the US National Cancer Institute from 1999-2001 and currently serves as CEO at biotech Lyell Immunopharma working with cell-based technology. He has also co-founded three US healthcare startups to date, Juno Therapeutics in 2013, MindStrong Health in 2014 and GRAIL in 2015. In 2021, he participated as an investor in the $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech.
Rick Klausner is an award-winning scientist, former executive director of the Bill & Melinda Gates Foundation and an entrepreneur. Cell and molecular biologist Klausner was also director of the US National Cancer Institute from 1999-2001 and currently serves as CEO at biotech Lyell Immunopharma working with cell-based technology. He has also co-founded three US healthcare startups to date, Juno Therapeutics in 2013, MindStrong Health in 2014 and GRAIL in 2015. In 2021, he participated as an investor in the $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech.
Vesalius Biocapital III is a €70 million fund that invests in medtech, e-health initiatives and drug development in Europe. It was launched in 2017 by Luxembourg-based Vesalius Biocapital, a life sciences venture capital firm founded in 2007. Preceding Vesalius Biocapital III were Vesalius Biocapital I, with €76 million under management and Vesalius Biocapital II, which has €78 million invested; both funds have 11 portfolio companies each.Its recent investments include in Portuguese home physiotherapy tech solution SWORD Health's 2021 $25m Series B and in the 2020 $9m second phase of its Series A round as well as in the 2020 €22m Series B round of German biotech Topas Therapeutics.
Vesalius Biocapital III is a €70 million fund that invests in medtech, e-health initiatives and drug development in Europe. It was launched in 2017 by Luxembourg-based Vesalius Biocapital, a life sciences venture capital firm founded in 2007. Preceding Vesalius Biocapital III were Vesalius Biocapital I, with €76 million under management and Vesalius Biocapital II, which has €78 million invested; both funds have 11 portfolio companies each.Its recent investments include in Portuguese home physiotherapy tech solution SWORD Health's 2021 $25m Series B and in the 2020 $9m second phase of its Series A round as well as in the 2020 €22m Series B round of German biotech Topas Therapeutics.
Daniel Oliver: Building a "Facebook" for investments in biotech startups
The biologist and crowdfunding expert has pioneered the growth of Spanish biotech startups, providing access to early-stage investments, with support from scientific experts worldwide
TreeFrog Therapeutics: Mimicking how stem cells grow in the human body
The French biotech’s proprietory technology to cultivate pluripotent stem cells in a 3D environment can be scaled to mass-produce high-quality cells to treat diseases such as Parkinson’s
ARTICARES: Personalized, more affordable arm rehab therapy at home
Using adaptive AI, its H-Man robot works like an occupational therapist, assessing patient’s performance and adjusting the complexity of training tasks in real time
Sorry, we couldn’t find any matches for“ZeCardio Therapeutics”.
POPULAR DATABASE
